Wikipedia -WSS

Wikipedia

author：focus 2025-10-04 11:35:46 - browse：95

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： J&J to buy cancer drug developer Ambrx Biopharma

focus

WSS

J&J to buy cancer drug developer Ambrx Biopharma

JPM: CVS says Medicare Advantage patients are impacting profits

Pharma patents targeted by Biden in move to slash drug prices

FDA approves world's first CRISPR

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

New weight loss drugs work. But how can they best be used?

knowledge

Wikipedia

hotspot

How to save PrEP access — and even expand it

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

The cancer drug shortage isn’t new — and neither are the solutions

U.K. sequencing study surfaces new findings about tumor DNA

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Teach medical students about patients with intellectual disabilities

The cancer drug shortage isn’t new — and neither are the solutions

Leukemia patients are helped by Syndax's new type of therapy

The high cost of giving birth even with insurance

3 medical device trends to watch in 2024

hotspot

Pregnancy discrimination could be enabled by AI

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Chemotherapy shortages won’t get better under Biden’s latest plan

J&J to buy cancer drug developer Ambrx Biopharma

Why psychiatrists like me stop taking insurance

In diabetes hearing, Sanders takes on a new foe: food makers

focus

focus

focus

focus